Business Wire

AFC Energy launches Hyamtec Limited (“Hyamtec”) to unlock the global hydrogen value chain

18.9.2024 09:00:00 CEST | Business Wire | Press release

Share

Delivering next generation Ammonia Cracking Technology

Hyamtec, the UK’s newest hydrogen company, has been launched by AFC Energy plc to deliver next generation modular ammonia cracking technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918101995/en/

Aerial view of ammonia cracker site (Photo: Business Wire)

Hyamtec can make on-site, on-demand hydrogen at just 10% of the cost of truck delivered hydrogen and will prioritise natural gas displacement in the hard to abate heavy industrial sectors which account for 50% of global carbon emissions.

Hyamtec will target areas which represent a £40 billion market in the UK alone:

  • Hydrogen rich combustible fuel gas for the decarbonisation of industrial heat generation;
  • Ammonia conversion of large combustion engines for power generation, marine and mining; and
  • Modular purified hydrogen production for fuel cells and transportation.

Hydrogen is the solution for decarbonisation of heavy industry and green hydrogen plants will dominate new capacity and by 2030, up to 20% of hydrogen produced globally will be green. This production will be located where the renewable energy required is abundant plentiful and cheap; however, hydrogen is difficult to store and transport, and it will take decades to install hydrogen pipelines. To transport the hydrogen to where it will be used, typically thousands of miles away, will require it to be moved as ammonia and then converted back to hydrogen.

Hyamtec’s technology can achieve this on-site at the lowest cost and highest efficiency to provide a solution to unlock industrial decarbonisation at scale. Hyamtec crackers have proven their ability to integrate with ammonia combustion engines (as a pilot fuel) and to deliver ISO Grade hydrogen for use in fuel cell applications.

Dr. Mike Rendall, Managing Director of Hyamtec Limited, said:

“Hyamtec is focused on fast tracking the decarbonisation of industry through ammonia and our ammonia cracking technologies. With over £40bn spent per annum on natural gas by industrial users in the UK alone, the global opportunity to displace fossil fuels in industry with ammonia is immense.

“The global journey to net zero will require the rapid development of hydrogen-based technologies. We look forward to partnering with industry to support the rapid decarbonisation of the world’s hardest to abate sectors and to announcing Hyamtec’s first commercial deals soon.”

Find out more at www.hyamtec.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918101995/en/

Contacts

Hyamtec Ltd

Hyamtec Ltd
Mike Rendall, Managing Director
+44 (0) 14 8327 6726
FTI Consulting – PR Advisors
afcenergy@fticonsulting.com

afcenergy@fticonsulting.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye